These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 19581184)

  • 21. FDA drug approval summary: panitumumab (Vectibix).
    Giusti RM; Shastri KA; Cohen MH; Keegan P; Pazdur R
    Oncologist; 2007 May; 12(5):577-83. PubMed ID: 17522246
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Integration of panitumumab into the treatment of colorectal cancer.
    Gravalos C; Cassinello J; García-Alfonso P; Jimeno A
    Crit Rev Oncol Hematol; 2010 Apr; 74(1):16-26. PubMed ID: 19616446
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer.
    Hecht JR; Mitchell E; Chidiac T; Scroggin C; Hagenstad C; Spigel D; Marshall J; Cohn A; McCollum D; Stella P; Deeter R; Shahin S; Amado RG
    J Clin Oncol; 2009 Feb; 27(5):672-80. PubMed ID: 19114685
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genentech caps cost of cancer drug for some patients.
    Pollack A
    N Y Times Web; 2006 Oct; ():C2. PubMed ID: 17061339
    [No Abstract]   [Full Text] [Related]  

  • 25. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer.
    Chase JL
    Pharmacotherapy; 2008 Nov; 28(11 Pt 2):23S-30S. PubMed ID: 18980549
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ramucirumab for Colon Cancer and the Problem of Rising Prices Independent of Benefits.
    Bach PB
    Oncologist; 2015 Sep; 20(9):983-4. PubMed ID: 26265223
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Colorectal cancer drugs market.
    Cassidy S; Syed BA
    Nat Rev Drug Discov; 2017 Aug; 16(8):525-526. PubMed ID: 28529321
    [No Abstract]   [Full Text] [Related]  

  • 28. [Minutes from the May 19th, 2006 meeting of the Oncology and Radiotherapy College. Location: National Institute of Oncology, Conference Hall. Present are 16 College members and invited guests].
    Moskovits K; Szucs M
    Magy Onkol; 2006; 50(3):265, 268-9, 271. PubMed ID: 17201055
    [No Abstract]   [Full Text] [Related]  

  • 29. Cost-effectiveness of cetuximab in combination with irinotecan compared with current care in metastatic colorectal cancer after failure on irinotecan--a Belgian analysis.
    Annemans L; Van Cutsem E; Humblet Y; Van Laethem JL; Bleiberg H
    Acta Clin Belg; 2007; 62(6):419-25. PubMed ID: 18351186
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan.
    Shiroiwa T; Fukuda T; Tsutani K
    Clin Ther; 2007 Oct; 29(10):2256-67. PubMed ID: 18042483
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rewarding value creation to promote innovation in oncology: The importance of considering the global product life cycle.
    Garrison LP
    Oncologist; 2010; 15 Suppl 1():49-57. PubMed ID: 20237218
    [No Abstract]   [Full Text] [Related]  

  • 32. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer.
    Hecht JR; Patnaik A; Berlin J; Venook A; Malik I; Tchekmedyian S; Navale L; Amado RG; Meropol NJ
    Cancer; 2007 Sep; 110(5):980-8. PubMed ID: 17671985
    [TBL] [Abstract][Full Text] [Related]  

  • 33. American Society of Clinical Oncology statement regarding the use of outside services to prepare or administer chemotherapy drugs.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 May; 21(9):1882-3. PubMed ID: 12668649
    [No Abstract]   [Full Text] [Related]  

  • 34. Cetuximab in colon cancer.
    Costa AF; Sander GB; Picon PD
    N Engl J Med; 2004 Oct; 351(15):1575-6; author reply 1575-6. PubMed ID: 15473024
    [No Abstract]   [Full Text] [Related]  

  • 35. Panitumumab: a fully human monoclonal antibody with activity in metastatic colorectal cancer.
    Saadeh CE; Lee HS
    Ann Pharmacother; 2007 Apr; 41(4):606-13. PubMed ID: 17355997
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New treatment options for colorectal cancer.
    Erlichman C; Sargent DJ
    N Engl J Med; 2004 Jul; 351(4):391-2. PubMed ID: 15269321
    [No Abstract]   [Full Text] [Related]  

  • 37. U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
    Giusti RM; Shastri K; Pilaro AM; Fuchs C; Cordoba-Rodriguez R; Koti K; Rothmann M; Men AY; Zhao H; Hughes M; Keegan P; Weiss KD; Pazdur R
    Clin Cancer Res; 2008 Mar; 14(5):1296-302. PubMed ID: 18316547
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Panitumumab in colorectal cancer.
    Wainberg ZA; Hecht JR
    Expert Rev Anticancer Ther; 2007 Jul; 7(7):967-73. PubMed ID: 17627455
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Panitumumab, a monoclonal anti epidermal growth factor receptor antibody in colorectal cancer: another one or the one?
    Messersmith WA; Hidalgo M
    Clin Cancer Res; 2007 Aug; 13(16):4664-6. PubMed ID: 17699842
    [No Abstract]   [Full Text] [Related]  

  • 40. Panitumumab.
    Saltz L; Easley C; Kirkpatrick P
    Nat Rev Drug Discov; 2006 Dec; 5(12):987-8. PubMed ID: 17201026
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.